In addition, drugs that are already used in clinical practice to delay disease progression, such as renin-angiotensin-aldosterone system blockers, not only prevent progressive renal damage but also promote the regression of glomerulosclerosis in several models of CKD (Remuzzi et al., 2006), suggesting that they may also exert their beneficial effects by promoting RPC differentiation into podocytes (Benigni et al., 2011). This evidence concerns the gene REN and glomerulosclerosis.